Artiva Biotherapeutics ARTV
NASDAQ ARTV
$7.11 +0.08 (+1.21%)
As of: Sep 30, 2026 · 3:59 PM EDT

Artiva Biotherapeutics (ARTV) Net Margin (2023 - 2024)

Updated

Artiva Biotherapeutics (ARTV) recorded Net Margin of -26045.02% in FY2024, down 25959.27 percentage points from -85.75% in FY2023.

Analysis

Artiva Biotherapeutics (ARTV) Net Margin (2023 - 2024) Analysis & Trends

  • Per Business Quant data, ARTV's Net Margin was -85.75% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 21.86%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 21.27%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -8.04%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 22.61%
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 18.81%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 23.62%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -134.51%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -1.65%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 32.99%
10 Artiva Biotherapeutics 277.08 Mn 277.08 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -5,562.95%
Dec 31, 2023 -510.55%
Sep 30, 2023 42.31%
Jun 30, 2023 -322.68%
API Access

Artiva Biotherapeutics Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=ARTV&period=max&api_key=YOUR_API_KEY